MK 2206 dihydrochloride，HY-10358，MCE

English 简体中文

首页 ∷ 试剂 ∷ MCE ∷ MK 2206 dihydrochloride

当前位置：

MK 2206 dihydrochloride

市场价： 0.00

价格： 0.00

商品描述

MK 2206 dihydrochloride:

Description

MK 2206 is an orally active allosteric Akt inhibitor with IC₅₀s of 5, 12 and 65 nM for Akt1, Akt2 and Akt3, respectively.

IC₅₀ & Target^[1]

Akt1

5 nM (IC₅₀)

Akt2

12 nM (IC₅₀)

Akt3

65 nM (IC₅₀)

Autophagy

In Vitro

The NPC cell lines CNE-1, CNE-2, HONE-1, and SUNE-1 are treated with increasing doses of MK-2206 (0-10 μM) for 72 and 96 hours, results in dose- and time-dependent inhibition of cell viability. At 72 and 96 hours, the IC₅₀ values of MK-2206 in CNE-1, CNE-2, and HONE-1 cell lines are 3-5 μM, and in SUNE-1, they are less than 1 μM. MK-2206 alone more potently inhibits the cell growth of Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292; IC₅₀s of 5.5, 4.3, and 5.2 μM, respectively) as compared with Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6; IC₅₀s of 13.5, 14.1, 27.0, and 28.6 μM, respectively), with the exception of NCI-H460, which has a PIK3CA E545K mutation (IC₅₀, 3.4 μM).

In Vivo

MK-2206 doses (480 mg/kg once a week and 240 mg/kg three times a week) can inhibit the growth of human CNE-2 xenografts in nude mice. In the two MK-2206 groups, the tumor weights are much lighter than the control group (P<0.01). Temporal body weight reduction is observed after receiving the MK-2206 treatment.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01519427	National Cancer Institute (NCI)	Recurrent Melanoma\|Stage IIIA Melanoma\|Stage IIIB Melanoma\|Stage IIIC Melanoma\|Stage IV Melanoma	January 2012	Phase 2
NCT01243762	Merck Sharp & Dohme Corp.	Neoplasms Malignant	November 22, 2010	Phase 1
NCT01239355	National Cancer Institute (NCI)	Adult Hepatocellular Carcinoma\|Advanced Adult Hepatocellular Carcinoma\|Localized Non-Resectable Adult Liver Carcinoma\|Recurrent Adult Liver Carcinoma	December 2010	Phase 2
NCT01283035	National Cancer Institute (NCI)	Ovarian Sarcoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	April 2011	Phase 2
NCT01239342	National Cancer Institute (NCI)\|M.D. Anderson Cancer Center	Metastatic Renal Cell Cancer\|Recurrent Renal Cell Carcinoma\|Stage IV Renal Cell Cancer	January 27, 2011	Phase 2
NCT01186705	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme Corp.	Colon Cancer\|Rectal Cancer	August 2010	Phase 2
NCT01349933	National Cancer Institute (NCI)	Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Nasopharynx	April 2011	Phase 2
NCT01295632	Merck Sharp & Dohme Corp.	Advanced Cancer	February 2011	Phase 1
NCT01231919	National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Acute Leukemias of Ambiguous Lineage\|Acute Myeloid Leukemia+Transient Myeloproliferative Disorder\|Acute Undifferentiated Leukemia\|Aggressive NK-cell Leukemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Blastic Plasmacytoid Dendritic Cell Neoplasm\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Grade III Lymphomatoid Granulomatosis\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Chronic Eosinophilic Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Intraocular Lymphoma\|Juvenile Myelomonocytic Leukemia\|Mast Cell Leukemia\|Myeloid+NK-cell Acute Leukemia\|Noncutaneous Extranodal Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Progressive Hairy Cell Leukemia, Initial Treatment\|Prolymphocytic Leukemia\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Unspecified Childhood Solid Tumor, Protocol Specific\|Waldenström Macroglobulinemia	January 2011	Phase 1
NCT01333475	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Colorectal Neoplasms	March 2011	Phase 2
NCT01239355	National Cancer Institute (NCI)	Adult Hepatocellular Carcinoma\|Advanced Adult Hepatocellular Carcinoma\|Localized Non-Resectable Adult Liver Carcinoma\|Recurrent Adult Liver Carcinoma	December 2010	Phase 2
NCT01277757	National Cancer Institute (NCI)	Recurrent Breast Carcinoma\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	March 2011	Phase 2
NCT01021748	Merck Sharp & Dohme Corp.\|AstraZeneca	Locally Advanced or Metastatic Solid Tumors	November 23, 2009	Phase 1
NCT01370070	Chinese University of Hong Kong	Recurrent Nasopharyngeal Carcinoma	July 2011	Phase 2
NCT01240941	Vanderbilt-Ingram Cancer Center	Metastatic Breast Cancer	February 2011	Phase 2
NCT01248247	M.D. Anderson Cancer Center\|Merck Sharp & Dohme Corp.\|National Cancer Institute (NCI)\|GlaxoSmithKline\|Novartis	Lung Cancer	June 2011	Phase 2
NCT01658943	National Cancer Institute (NCI)	Pancreatic Acinar Cell Carcinoma\|Pancreatic Ductal Adenocarcinoma\|Recurrent Pancreatic Carcinoma\|Stage IV Pancreatic Cancer	August 2012	Phase 2
NCT01306045	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Carcinoma, Non-Small-Cell Lung\|Carcinoma, Small Cell Lung\|Carcinoma, Thymic	February 26, 2011	Phase 2
NCT01021748	Merck Sharp & Dohme Corp.\|AstraZeneca	Locally Advanced or Metastatic Solid Tumors	November 23, 2009	Phase 1
NCT01294306	National Cancer Institute (NCI)	Adenosquamous Lung Carcinoma\|Bronchioloalveolar Carcinoma\|Large Cell Lung Carcinoma\|Lung Adenocarcinoma\|Recurrent Non-Small Cell Lung Carcinoma\|Squamous Cell Lung Carcinoma	February 2011	Phase 2
NCT01248247	M.D. Anderson Cancer Center\|Merck Sharp & Dohme Corp.\|National Cancer Institute (NCI)\|GlaxoSmithKline\|Novartis	Lung Cancer	June 2011	Phase 2
NCT01277757	National Cancer Institute (NCI)	Recurrent Breast Carcinoma\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer	March 2011	Phase 2
NCT01231919	National Cancer Institute (NCI)	Accelerated Phase Chronic Myelogenous Leukemia\|Acute Leukemias of Ambiguous Lineage\|Acute Myeloid Leukemia+Transient Myeloproliferative Disorder\|Acute Undifferentiated Leukemia\|Aggressive NK-cell Leukemia\|Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative\|Blastic Phase Chronic Myelogenous Leukemia\|Blastic Plasmacytoid Dendritic Cell Neoplasm\|Childhood Burkitt Lymphoma\|Childhood Chronic Myelogenous Leukemia\|Childhood Diffuse Large Cell Lymphoma\|Childhood Grade III Lymphomatoid Granulomatosis\|Childhood Immunoblastic Large Cell Lymphoma\|Childhood Nasal Type Extranodal NK+T-cell Lymphoma\|Chronic Eosinophilic Leukemia\|Chronic Myelomonocytic Leukemia\|Chronic Neutrophilic Leukemia\|Chronic Phase Chronic Myelogenous Leukemia\|Intraocular Lymphoma\|Juvenile Myelomonocytic Leukemia\|Mast Cell Leukemia\|Myeloid+NK-cell Acute Leukemia\|Noncutaneous Extranodal Lymphoma\|Post-transplant Lymphoproliferative Disorder\|Primary Central Nervous System Hodgkin Lymphoma\|Primary Central Nervous System Non-Hodgkin Lymphoma\|Progressive Hairy Cell Leukemia, Initial Treatment\|Prolymphocytic Leukemia\|Recurrent Childhood Acute Lymphoblastic Leukemia\|Recurrent Childhood Acute Myeloid Leukemia\|Recurrent Childhood Anaplastic Large Cell Lymphoma\|Recurrent Childhood Grade III Lymphomatoid Granulomatosis\|Recurrent Childhood Large Cell Lymphoma\|Recurrent Childhood Lymphoblastic Lymphoma\|Recurrent Childhood Small Noncleaved Cell Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Recurrent+Refractory Childhood Hodgkin Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Refractory Hairy Cell Leukemia\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Unspecified Childhood Solid Tumor, Protocol Specific\|Waldenström Macroglobulinemia	January 2011	Phase 1
NCT01251861	National Cancer Institute (NCI)	Recurrent Prostate Carcinoma\|Stage I Prostate Cancer AJCC v7\|Stage IIA Prostate Cancer AJCC v7\|Stage IIB Prostate Cancer AJCC v7\|Stage III Prostate Cancer AJCC v7	December 23, 2010	Phase 2
NCT01245205	National Cancer Institute (NCI)	HER2-positive Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	November 2010	Phase 1
NCT01260701	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction\|Diffuse Gastric Adenocarcinoma\|Gastric Intestinal Type Adenocarcinoma\|Gastric Mixed Adenocarcinoma\|Recurrent Gastric Carcinoma	January 2011	Phase 2
NCT01235897	University of California, San Francisco\|Merck Sharp & Dohme Corp.	Advanced Solid Tumors\|Tumors\|Cancer	March 2011	Phase 1
NCT01425879	National Cancer Institute (NCI)	Advanced Adult Hepatocellular Carcinoma\|Localized Non-Resectable Adult Liver Carcinoma\|Recurrent Adult Liver Carcinoma\|Recurrent Gallbladder Carcinoma\|Stage IV Distal Bile Duct Cancer\|Stage IV Gallbladder Cancer\|Unresectable Extrahepatic Bile Duct Carcinoma\|Unresectable Gallbladder Carcinoma	April 2011	Phase 2
NCT01859182	National Cancer Institute (NCI)	Adenocarcinoma of the Gallbladder\|Adenocarcinoma With Squamous Metaplasia of the Gallbladder\|Adult Primary Cholangiocellular Carcinoma\|Advanced Adult Primary Liver Cancer\|Cholangiocarcinoma of the Extrahepatic Bile Duct\|Localized Unresectable Adult Primary Liver Cancer\|Metastatic Extrahepatic Bile Duct Cancer\|Recurrent Adult Primary Liver Cancer\|Recurrent Extrahepatic Bile Duct Cancer\|Stage II Gallbladder Cancer\|Stage IIIA Gallbladder Cancer\|Stage IIIB Gallbladder Cancer\|Stage IVA Gallbladder Cancer\|Stage IVB Gallbladder Cancer\|Unresectable Extrahepatic Bile Duct Cancer	January 2013	Phase 2
NCT01480154	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Hormone-Resistant Prostate Carcinoma\|Recurrent Melanoma\|Recurrent Prostate Carcinoma\|Recurrent Renal Cell Carcinoma\|Stage IIIA Cutaneous Melanoma AJCC v7\|Stage IIIB Cutaneous Melanoma AJCC v7\|Stage IIIC Cutaneous Melanoma AJCC v7\|Stage IV Cutaneous Melanoma AJCC v6 and v7\|Stage IV Prostate Cancer AJCC v7\|Stage IV Renal Cell Cancer AJCC v7	November 23, 2011	Phase 1
NCT01281163	National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Positive\|Progesterone Receptor Negative\|Progesterone Receptor Positive\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 2011	Phase 1
NCT01307631	National Cancer Institute (NCI)	Endometrial Adenocarcinoma\|Endometrial Adenosquamous Carcinoma\|Endometrial Clear Cell Adenocarcinoma\|Endometrial Serous Adenocarcinoma\|Recurrent Uterine Corpus Carcinoma	March 2011	Phase 2
NCT01349933	National Cancer Institute (NCI)	Recurrent Squamous Cell Carcinoma of the Nasopharynx\|Stage IV Squamous Cell Carcinoma of the Nasopharynx	April 2011	Phase 2
NCT01258998	National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenström Macroglobulinemia	December 2010	Phase 2
NCT01370070	Chinese University of Hong Kong	Recurrent Nasopharyngeal Carcinoma	July 2011	Phase 2
NCT01240941	Vanderbilt-Ingram Cancer Center	Metastatic Breast Cancer	February 2011	Phase 2
NCT01519427	National Cancer Institute (NCI)	Recurrent Melanoma\|Stage IIIA Melanoma\|Stage IIIB Melanoma\|Stage IIIC Melanoma\|Stage IV Melanoma	January 2012	Phase 2
NCT01071018	Merck Sharp & Dohme Corp.	Solid Tumors	February 2010	Phase 1
NCT01859182	National Cancer Institute (NCI)	Adenocarcinoma of the Gallbladder\|Adenocarcinoma With Squamous Metaplasia of the Gallbladder\|Adult Primary Cholangiocellular Carcinoma\|Advanced Adult Primary Liver Cancer\|Cholangiocarcinoma of the Extrahepatic Bile Duct\|Localized Unresectable Adult Primary Liver Cancer\|Metastatic Extrahepatic Bile Duct Cancer\|Recurrent Adult Primary Liver Cancer\|Recurrent Extrahepatic Bile Duct Cancer\|Stage II Gallbladder Cancer\|Stage IIIA Gallbladder Cancer\|Stage IIIB Gallbladder Cancer\|Stage IVA Gallbladder Cancer\|Stage IVB Gallbladder Cancer\|Unresectable Extrahepatic Bile Duct Cancer	January 2013	Phase 2
NCT01369849	National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia	September 2011	Phase 1\|Phase 2
NCT01480154	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Hormone-Resistant Prostate Carcinoma\|Recurrent Melanoma\|Recurrent Prostate Carcinoma\|Recurrent Renal Cell Carcinoma\|Stage IIIA Cutaneous Melanoma AJCC v7\|Stage IIIB Cutaneous Melanoma AJCC v7\|Stage IIIC Cutaneous Melanoma AJCC v7\|Stage IV Cutaneous Melanoma AJCC v6 and v7\|Stage IV Prostate Cancer AJCC v7\|Stage IV Renal Cell Cancer AJCC v7	November 23, 2011	Phase 1
NCT01042379	QuantumLeap Healthcare Collaborative	Breast Neoplasms\|Breast Cancer\|Breast Tumors	March 2010	Phase 2
NCT01705340	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction\|HER2-positive Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Recurrent Esophageal Cancer\|Recurrent Gastric Cancer\|Stage IIIC Breast Cancer\|Stage IIIC Esophageal Cancer\|Stage IIIC Gastric Cancer\|Stage IV Breast Cancer\|Stage IV Esophageal Cancer\|Stage IV Gastric Cancer	September 2012	Phase 1
NCT01369849	National Cancer Institute (NCI)	Chronic Lymphocytic Leukemia\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia	September 2011	Phase 1\|Phase 2
NCT00670488	Merck Sharp & Dohme Corp.	Locally Advanced Tumors\|Metastatic Solid Tumors\|Cancer\|Neoplasms	April 2008	Phase 1
NCT00848718	Merck Sharp & Dohme Corp.	Locally Advanced, Metastatic Solid Tumors	March 2009	Phase 1
NCT01147211	National Taiwan University Hospital	Non Small Cell Lung Cancer	September 2010	Phase 1
NCT01263145	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 5, 2011	Phase 1
NCT01776008	National Cancer Institute (NCI)	Estrogen Receptor Positive\|HER2+Neu Negative\|Recurrent Breast Carcinoma\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer	January 2013	Phase 2
NCT01658943	National Cancer Institute (NCI)	Pancreatic Acinar Cell Carcinoma\|Pancreatic Ductal Adenocarcinoma\|Recurrent Pancreatic Carcinoma\|Stage IV Pancreatic Cancer	August 2012	Phase 2
NCT01169649	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme Corp.	PANCREAS\|Neuroendocrine	July 2010	Phase 2
NCT01253447	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	October 2010	Phase 2
NCT01425879	National Cancer Institute (NCI)	Advanced Adult Hepatocellular Carcinoma\|Localized Non-Resectable Adult Liver Carcinoma\|Recurrent Adult Liver Carcinoma\|Recurrent Gallbladder Carcinoma\|Stage IV Distal Bile Duct Cancer\|Stage IV Gallbladder Cancer\|Unresectable Extrahepatic Bile Duct Carcinoma\|Unresectable Gallbladder Carcinoma	April 2011	Phase 2
NCT01783171	National Cancer Institute (NCI)	Pancreatic Adenocarcinoma\|Recurrent Pancreatic Carcinoma\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Pancreatic Carcinoma	January 15, 2013	Phase 1
NCT01306045	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Carcinoma, Non-Small-Cell Lung\|Carcinoma, Small Cell Lung\|Carcinoma, Thymic	February 26, 2011	Phase 2
NCT00670488	Merck Sharp & Dohme Corp.	Locally Advanced Tumors\|Metastatic Solid Tumors\|Cancer\|Neoplasms	April 2008	Phase 1
NCT01249105	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Memorial Sloan Kettering Cancer Center\|University of California, Los Angeles\|Merck Sharp & Dohme Corp.	Malignant Glioma		Phase 2
NCT01466868	Centre Leon Berard\|National Cancer Institute, France	Diffuse Large B Cell Lymphoma	November 2011	Phase 2
NCT01783171	National Cancer Institute (NCI)	Pancreatic Adenocarcinoma\|Recurrent Pancreatic Carcinoma\|Stage III Pancreatic Cancer AJCC v6 and v7\|Stage IV Pancreatic Cancer AJCC v6 and v7\|Unresectable Pancreatic Carcinoma	January 15, 2013	Phase 1
NCT01239342	National Cancer Institute (NCI)\|M.D. Anderson Cancer Center	Metastatic Renal Cell Cancer\|Recurrent Renal Cell Carcinoma\|Stage IV Renal Cell Cancer	January 27, 2011	Phase 2
NCT01186705	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme Corp.	Colon Cancer\|Rectal Cancer	August 2010	Phase 2
NCT01604772	National Cancer Institute (NCI)	Recurrent Oral Cavity Adenoid Cystic Carcinoma\|Recurrent Salivary Gland Carcinoma\|Salivary Gland Adenoid Cystic Carcinoma\|Stage IVA Major Salivary Gland Cancer AJCC v7\|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVB Major Salivary Gland Cancer AJCC v7\|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVC Major Salivary Gland Cancer AJCC v7\|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7	July 23, 2012	Phase 2
NCT00963547	Merck Sharp & Dohme Corp.	Advanced Solid Tumors\|Breast Cancer	September 15, 2009	Phase 1
NCT01333475	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Colorectal Neoplasms	March 2011	Phase 2
NCT01258998	National Cancer Institute (NCI)	Adult Nasal Type Extranodal NK+T-cell Lymphoma\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|B-cell Adult Acute Lymphoblastic Leukemia\|B-cell Chronic Lymphocytic Leukemia\|Cutaneous B-cell Non-Hodgkin Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Hepatosplenic T-cell Lymphoma\|Intraocular Lymphoma\|Nodal Marginal Zone B-cell Lymphoma\|Noncutaneous Extranodal Lymphoma\|Peripheral T-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult Diffuse Mixed Cell Lymphoma\|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma\|Recurrent Adult Grade III Lymphomatoid Granulomatosis\|Recurrent Adult Hodgkin Lymphoma\|Recurrent Adult Immunoblastic Large Cell Lymphoma\|Recurrent Adult Lymphoblastic Lymphoma\|Recurrent Adult T-cell Leukemia+Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides+Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Hairy Cell Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|T-cell Adult Acute Lymphoblastic Leukemia\|T-cell Large Granular Lymphocyte Leukemia\|Testicular Lymphoma\|Waldenström Macroglobulinemia	December 2010	Phase 2
NCT01251861	National Cancer Institute (NCI)	Recurrent Prostate Carcinoma\|Stage I Prostate Cancer AJCC v7\|Stage IIA Prostate Cancer AJCC v7\|Stage IIB Prostate Cancer AJCC v7\|Stage III Prostate Cancer AJCC v7	December 23, 2010	Phase 2
NCT01776008	National Cancer Institute (NCI)	Estrogen Receptor Positive\|HER2+Neu Negative\|Recurrent Breast Carcinoma\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer	January 2013	Phase 2
NCT01042379	QuantumLeap Healthcare Collaborative	Breast Neoplasms\|Breast Cancer\|Breast Tumors	March 2010	Phase 2
NCT01319539	National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Negative\|HER2+Neu Positive\|Progesterone Receptor Negative\|Progesterone Receptor Positive\|Stage IA Breast Cancer\|Stage IB Breast Cancer\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Triple-Negative Breast Carcinoma	April 2011	Phase 2
NCT00848718	Merck Sharp & Dohme Corp.	Locally Advanced, Metastatic Solid Tumors	March 2009	Phase 1
NCT01604772	National Cancer Institute (NCI)	Recurrent Oral Cavity Adenoid Cystic Carcinoma\|Recurrent Salivary Gland Carcinoma\|Salivary Gland Adenoid Cystic Carcinoma\|Stage IVA Major Salivary Gland Cancer AJCC v7\|Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVB Major Salivary Gland Cancer AJCC v7\|Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7\|Stage IVC Major Salivary Gland Cancer AJCC v7\|Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7	July 23, 2012	Phase 2
NCT01243762	Merck Sharp & Dohme Corp.	Neoplasms Malignant	November 22, 2010	Phase 1
NCT01705340	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction\|HER2-positive Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Recurrent Esophageal Cancer\|Recurrent Gastric Cancer\|Stage IIIC Breast Cancer\|Stage IIIC Esophageal Cancer\|Stage IIIC Gastric Cancer\|Stage IV Breast Cancer\|Stage IV Esophageal Cancer\|Stage IV Gastric Cancer	September 2012	Phase 1
NCT01481129	National Cancer Institute (NCI)	Diffuse Large B Cell Lymphoma	December 2011	Phase 2
NCT01071018	Merck Sharp & Dohme Corp.	Solid Tumors	February 2010	Phase 1
NCT01319539	National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Negative\|HER2+Neu Positive\|Progesterone Receptor Negative\|Progesterone Receptor Positive\|Stage IA Breast Cancer\|Stage IB Breast Cancer\|Stage IIA Breast Cancer\|Stage IIB Breast Cancer\|Stage IIIA Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Triple-Negative Breast Carcinoma	April 2011	Phase 2
NCT01263145	National Cancer Institute (NCI)	Adult Solid Neoplasm\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 5, 2011	Phase 1
NCT01344031	National Cancer Institute (NCI)	Estrogen Receptor Positive\|Invasive Breast Carcinoma\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer AJCC v6 and v7	April 21, 2011	Phase 1
NCT01802320	National Cancer Institute (NCI)	Colon Mucinous Adenocarcinoma\|Colon Signet Ring Cell Adenocarcinoma\|Rectal Mucinous Adenocarcinoma\|Rectal Signet Ring Cell Adenocarcinoma\|Recurrent Colon Carcinoma\|Recurrent Rectal Carcinoma\|Stage IIIA Colon Cancer\|Stage IIIA Rectal Cancer\|Stage IIIB Colon Cancer\|Stage IIIB Rectal Cancer\|Stage IIIC Colon Cancer\|Stage IIIC Rectal Cancer\|Stage IVA Colon Cancer\|Stage IVA Rectal Cancer\|Stage IVB Colon Cancer\|Stage IVB Rectal Cancer	March 2013	Phase 2
NCT01802320	National Cancer Institute (NCI)	Colon Mucinous Adenocarcinoma\|Colon Signet Ring Cell Adenocarcinoma\|Rectal Mucinous Adenocarcinoma\|Rectal Signet Ring Cell Adenocarcinoma\|Recurrent Colon Carcinoma\|Recurrent Rectal Carcinoma\|Stage IIIA Colon Cancer\|Stage IIIA Rectal Cancer\|Stage IIIB Colon Cancer\|Stage IIIB Rectal Cancer\|Stage IIIC Colon Cancer\|Stage IIIC Rectal Cancer\|Stage IVA Colon Cancer\|Stage IVA Rectal Cancer\|Stage IVB Colon Cancer\|Stage IVB Rectal Cancer	March 2013	Phase 2
NCT01147211	National Taiwan University Hospital	Non Small Cell Lung Cancer	September 2010	Phase 1
NCT01260701	National Cancer Institute (NCI)	Adenocarcinoma of the Gastroesophageal Junction\|Diffuse Gastric Adenocarcinoma\|Gastric Intestinal Type Adenocarcinoma\|Gastric Mixed Adenocarcinoma\|Recurrent Gastric Carcinoma	January 2011	Phase 2
NCT01169649	Memorial Sloan Kettering Cancer Center\|Merck Sharp & Dohme Corp.	PANCREAS\|Neuroendocrine	July 2010	Phase 2
NCT01253447	National Cancer Institute (NCI)	Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Del(5q)\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Recurrent Adult Acute Myeloid Leukemia	October 2010	Phase 2
NCT01295632	Merck Sharp & Dohme Corp.	Advanced Cancer	February 2011	Phase 1
NCT01245205	National Cancer Institute (NCI)	HER2-positive Breast Cancer\|Male Breast Cancer\|Recurrent Breast Cancer\|Stage IIIB Breast Cancer\|Stage IIIC Breast Cancer\|Stage IV Breast Cancer\|Unspecified Adult Solid Tumor, Protocol Specific	November 2010	Phase 1
NCT01481129	National Cancer Institute (NCI)	Diffuse Large B Cell Lymphoma	December 2011	Phase 2
NCT01283035	National Cancer Institute (NCI)	Ovarian Sarcoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	April 2011	Phase 2
NCT01281163	National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Positive\|Progesterone Receptor Negative\|Progesterone Receptor Positive\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 2011	Phase 1
NCT01249105	Dana-Farber Cancer Institute\|Brigham and Women´s Hospital\|Massachusetts General Hospital\|Beth Israel Deaconess Medical Center\|Memorial Sloan Kettering Cancer Center\|University of California, Los Angeles\|Merck Sharp & Dohme Corp.	Malignant Glioma		Phase 2
NCT01344031	National Cancer Institute (NCI)	Estrogen Receptor Positive\|Invasive Breast Carcinoma\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer AJCC v6 and v7	April 21, 2011	Phase 1
NCT00963547	Merck Sharp & Dohme Corp.	Advanced Solid Tumors\|Breast Cancer	September 15, 2009	Phase 1
NCT01466868	Centre Leon Berard\|National Cancer Institute, France	Diffuse Large B Cell Lymphoma	November 2011	Phase 2
NCT01307631	National Cancer Institute (NCI)	Endometrial Adenocarcinoma\|Endometrial Adenosquamous Carcinoma\|Endometrial Clear Cell Adenocarcinoma\|Endometrial Serous Adenocarcinoma\|Recurrent Uterine Corpus Carcinoma	March 2011	Phase 2
NCT01235897	University of California, San Francisco\|Merck Sharp & Dohme Corp.	Advanced Solid Tumors\|Tumors\|Cancer	March 2011	Phase 1
NCT01294306	National Cancer Institute (NCI)	Adenosquamous Lung Carcinoma\|Bronchioloalveolar Carcinoma\|Large Cell Lung Carcinoma\|Lung Adenocarcinoma\|Recurrent Non-Small Cell Lung Carcinoma\|Squamous Cell Lung Carcinoma	February 2011	Phase 2

Solvent & Solubility

In Vitro:

DMSO : 4.9 mg/mL (10.20 mM; Need ultrasonic and warming)

H₂O : 3.81 mg/mL (7.93 mM; Need ultrasonic and warming)

Preparing
Stock Solutions

ConcentrationSolventMass	1 mg	5 mg	10 mg

1 mM	2.0816 mL	10.4082 mL	20.8164 mL
5 mM	0.4163 mL	2.0816 mL	4.1633 mL
10 mM	0.2082 mL	1.0408 mL	2.0816 mL

*Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

MK 2206 is prepared in vehicle (30% captisol).
2.

MK 2206 dihydrochloride is prepared in Vehicle (corn oil+5% DMSO).

相关产品：

品牌	货号	名称	规格
MCE	HY-100406-50MG	(S)-MCPG
MCE	HY-100421	CPI-455	5MG
MCE	HY-10071-1ml	Y-27632	1ml
MCE	HY-10071-50mg	Y-27632	50mg
MCE	HY-10108	LY294002	10 mM * 1 mL
MCE	HY-101091-5mg	Importazole	5mg
MCE	HY-101391-100mg	Picrotoxin	100mg
MCE	HY-101494-1MG	LY3214996
MCE	HY-10182 -1ml	CHIR-99021	1ml
MCE	HY-10219-10MG	Rapamycin
MCE	HY-10219-25MG	Rapamycin
MCE	HY-10254-1ml	PD0325901	1ml
MCE	HY-10358	MK 2206 dihydrochloride	10 mM * 1 mL
MCE	HY-10583-1ml	Y-27632 (dihydrochloride)	1ml
MCE	HY-10627A-50mg	GW3965 hydrochloride
MCE	HY-10627A-5MG	GW3965 hydrochloride
MCE	HY-108709 -1mg	CC-671	1mg
MCE	HY-10997-10MG	PCI-32765
MCE	HY-12028	PD98059	10 mM * 1 mL
MCE	HY-12028-5MG	PD98059
MCE	HY-12275	FR 180204	10 mM * 1 mL
MCE	HY-12466-1mg	Z-DEVD-FMK	1mg
MCE	HY-12526	Tetrodotoxin	1MG
MCE	HY-13315-50MG	Montelukast sodium	50MG
MCE	HY-13316	Mitomycin C	5MG
MCE	HY-13688A-10MG	PJ34
MCE	HY-14166-100MG	MK-886
MCE	HY-15310-500mg	Ivermectin	500mg
MCE	HY-15893-50mg	DMOG	50mg
MCE	HY-16563-1mg	Narciclasine	1mg
MCE	HY-17026-100mg	Gemcitabine	100mg
MCE	HY-17356-10g	Fenofibrate
MCE	HY-17382	Metoclopramide	100MG
MCE	HY-17538-10MG	ZLN005	10MG
MCE	HY-17561-5G	G-418 disulfate	5G
MCE	HY-17567-100mg	Heparin	100mg
MCE	HY-17567A-100mg	Heparin sodium salt	100mg
MCE	HY-17589-100MG	Chloroquine diphosphate
MCE	HY-18012	AVL-292	10MG
MCE	HY-19312-500MG	3-Methyladenine
MCE	HY-19312-50mg	3-Methyladenine	50mg
MCE	HY-19538-1mg	FRAX1036	1mg
MCE	HY-50846-2MG	SCH772984
MCE	HY-50907-1ml	ABT-737	1ml
MCE	HY-66009-1ml	Epalrestat	1ml
MCE	HY-B0089	Acarbose	200MG
MCE	HY-B0141-1G	Estradiol	1g
MCE	HY-B0795-5MG	MHY1485
MCE	HY-B0919-1ml	Azaserine	1ml
MCE	HY-B1041-1ml	Aminoguanidine hydrochloride	1ml
MCE	HY-B1743A	Puromycin dihydrochloride	10 mM * 1 mL
MCE	HY-B1756-5g	Rotenone	5g
MCE	HY-N0219	(+)-Bicuculline	100MG
MCE	HY-N0390-100mg	L-Glutamine	100mg
MCE	HY-N0583 -1G	Hydrocortisone	1g
MCE	HY-P0035-10mg	Insulin(human)	10mg
MCE	HY-P7011-10ug	Recombinant Human Epiregulin	10ug
MCE	HY-P7154-10ug	Recombinant Mouse DKK-1 (CHO-expressed)	10ug

上一个： Y-27632 dihydrochloride

下一个： PD0325901

联系微信

用户至上，用心服务

联系QQ

联系地址：广州市海珠区新滘中路161号广骏商务中心423室（地铁：3号线大塘站）
电话：020-29842979
传真：020-29842979

020-29842979

Sale Hotline

联系我们

友情链接

喀斯玛平台